<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094648</url>
  </required_header>
  <id_info>
    <org_study_id>nasal therapy in covid patient</org_study_id>
    <nct_id>NCT05094648</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Therapy in Covid 19 Patient</brief_title>
  <official_title>Predictors of Success of High Flow Nasal Therapy in Covid 19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maha Mahmoud Ahmed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to To identify factors that predict success of high flow nasal therapy in&#xD;
      covid19 patients .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease 2019 (COVID-19) is a potentially fatal infection caused by the novel&#xD;
      severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)[1]. The highly contagious nature&#xD;
      and exponential spread of SARS-CoV-2, coupled with its potential for a rapid progressto acute&#xD;
      respiratory distress syndrome (ARDS), has overwhelmed health care systems globally,&#xD;
      contributing to the high mortality rates in early reports [1,2].&#xD;
&#xD;
      The initial approach for respiratory support for severe COVID-19 pneumonia centredaround&#xD;
      invasive mechanical ventilation and the standard lung protective strategy recommended for&#xD;
      ARDS[3]. This may have been detrimental to a proportion of patients due to ventilator induced&#xD;
      lung injury (VILI) and associated systemic inflammation[4]. Furthermore, other strategies to&#xD;
      improve oxygenation may be more appropriate in patients with hypoxemic respiratory failure&#xD;
      who do not require ventilatorysupport[4].&#xD;
&#xD;
      High-flow nasal oxygen (HFNO) is delivered by an air/oxygen blender, an active humidifier, a&#xD;
      single heated circuit, and a nasal interface.&#xD;
&#xD;
      It delivers adequately heated and humidified medical gas at flow-rates of up to 60L/min, and&#xD;
      is considered to have a number of physiological benefits, including the reduction of&#xD;
      anatomical dead space and work of breathing, the provision of a constant fraction of inspired&#xD;
      oxygen with adequate humidification and a degree of positive end-expiratory pressure (PEEP)&#xD;
      [5,6].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>predictors of success of high flow nasal therapy in covid 19 patients</measure>
    <time_frame>Baseline</time_frame>
    <description>This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>High Flow Nasal Therapy</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <description>Covidpatient Who pass on high flow nasal therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <description>Covidpatient who failed on high flow nasal therapy and need NIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high flow nasal therapy</intervention_name>
    <description>effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. demographic data including age, sex, smoking history, educational level.&#xD;
&#xD;
          2. Duration of illness before admission, clinical presentation, presence of co&#xD;
             morbidities, BMI.&#xD;
&#xD;
          3. Vital signs, and radiologic findings&#xD;
&#xD;
          4. ABG at admission and (half an hour, 2hr, 24 hr, and 48hr)later on.&#xD;
&#xD;
          5. SPO2, FIO2, and respiratory rate at admission for calculating ROX index&#xD;
             (SPO2/FIO2)/RR.&#xD;
&#xD;
          6. GCC, and APACHI score at time of admission.&#xD;
&#xD;
          7. Inflammatory markers at time of admission (CBC with differential, CRP, ferritin, D&#xD;
             dimer, LDH), in addition to liver and renal function.&#xD;
&#xD;
        At the end of the study patients will be claccifiedin to two groups based on success of&#xD;
        high flow nasal therapy:&#xD;
&#xD;
        Group A Covidpatient Who pass on high flow nasal therapy Group B Covidpatient who failed on&#xD;
        nasal therapy and need NIV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Patients above 18 y old that will be diagnosed as COVID 19 based on PCR testing,&#xD;
             who fulfil criteria that indicate need for high flow nasal therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  o Children less than 18 y old&#xD;
&#xD;
               -  Oropharyngeal and Nasopharyngeal swap negative patients&#xD;
&#xD;
               -  Patients who will refuse inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maha Mahmoud</last_name>
    <phone>01063453193</phone>
    <email>maha.mahmoud.1994@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>samiaa sadik</last_name>
    <phone>01006769597</phone>
    <email>samiaa_sadek@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Nishimura M. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects. Respir Care. 2016 Apr;61(4):529-41. doi: 10.4187/respcare.04577. Review.</citation>
    <PMID>27016353</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Maha Mahmoud Ahmed</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

